Challenges for gene therapy of type 1 diabetes.

H. Dong, K. Anthony, Nuria Morral

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Type 1 or insulin-dependent diabetes mellitus is caused by autoimmune attack and selective destruction of the pancreatic beta cells. Despite the development of various insulin replacement therapies, insulin injection still remains the mainstay treatment for type 1 diabetes. However, exogenous insulin administration cannot achieve the same degree of glycemic control as provided by endogenous insulin produced from the pancreatic beta cells. Insulin gene transfer is being developed to improve the quality of glycemic control by restoring endogenous insulin production in type 1 diabetes. Nevertheless, attempts to achieve adequately regulated insulin production are stymied by the lack of appropriate surrogate cells that are able to detect blood glucose variations and release insulin in a glucose-dependent manner. Although limited success has been made to control insulin gene expression in ectopic cells using hormone/glucose-regulated expression systems, these transcriptionally regulated systems are relatively slow in the "on-" and "off"-kinetics of insulin production, raising a serious safety concern for clinical application. In this article, we will review recent advances made to address this concern and highlight the importance of insulin gene transfer to cell types that possess an intrinsic ability to kinetically mimic the pancreatic beta cells in terms of glucose-responsive insulin secretion.

Original languageEnglish (US)
Pages (from-to)403-414
Number of pages12
JournalCurrent Gene Therapy
Volume2
Issue number4
StatePublished - Dec 2002
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Genetic Therapy
Insulin
Insulin-Secreting Cells
Glucose
Quality Control
Genes
Blood Glucose
Hormones
Safety
Injections

ASJC Scopus subject areas

  • Genetics

Cite this

Challenges for gene therapy of type 1 diabetes. / Dong, H.; Anthony, K.; Morral, Nuria.

In: Current Gene Therapy, Vol. 2, No. 4, 12.2002, p. 403-414.

Research output: Contribution to journalArticle

Dong, H, Anthony, K & Morral, N 2002, 'Challenges for gene therapy of type 1 diabetes.', Current Gene Therapy, vol. 2, no. 4, pp. 403-414.
Dong, H. ; Anthony, K. ; Morral, Nuria. / Challenges for gene therapy of type 1 diabetes. In: Current Gene Therapy. 2002 ; Vol. 2, No. 4. pp. 403-414.
@article{89c6b96307e7445d8cd2e4a72122e7ad,
title = "Challenges for gene therapy of type 1 diabetes.",
abstract = "Type 1 or insulin-dependent diabetes mellitus is caused by autoimmune attack and selective destruction of the pancreatic beta cells. Despite the development of various insulin replacement therapies, insulin injection still remains the mainstay treatment for type 1 diabetes. However, exogenous insulin administration cannot achieve the same degree of glycemic control as provided by endogenous insulin produced from the pancreatic beta cells. Insulin gene transfer is being developed to improve the quality of glycemic control by restoring endogenous insulin production in type 1 diabetes. Nevertheless, attempts to achieve adequately regulated insulin production are stymied by the lack of appropriate surrogate cells that are able to detect blood glucose variations and release insulin in a glucose-dependent manner. Although limited success has been made to control insulin gene expression in ectopic cells using hormone/glucose-regulated expression systems, these transcriptionally regulated systems are relatively slow in the {"}on-{"} and {"}off{"}-kinetics of insulin production, raising a serious safety concern for clinical application. In this article, we will review recent advances made to address this concern and highlight the importance of insulin gene transfer to cell types that possess an intrinsic ability to kinetically mimic the pancreatic beta cells in terms of glucose-responsive insulin secretion.",
author = "H. Dong and K. Anthony and Nuria Morral",
year = "2002",
month = "12",
language = "English (US)",
volume = "2",
pages = "403--414",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Challenges for gene therapy of type 1 diabetes.

AU - Dong, H.

AU - Anthony, K.

AU - Morral, Nuria

PY - 2002/12

Y1 - 2002/12

N2 - Type 1 or insulin-dependent diabetes mellitus is caused by autoimmune attack and selective destruction of the pancreatic beta cells. Despite the development of various insulin replacement therapies, insulin injection still remains the mainstay treatment for type 1 diabetes. However, exogenous insulin administration cannot achieve the same degree of glycemic control as provided by endogenous insulin produced from the pancreatic beta cells. Insulin gene transfer is being developed to improve the quality of glycemic control by restoring endogenous insulin production in type 1 diabetes. Nevertheless, attempts to achieve adequately regulated insulin production are stymied by the lack of appropriate surrogate cells that are able to detect blood glucose variations and release insulin in a glucose-dependent manner. Although limited success has been made to control insulin gene expression in ectopic cells using hormone/glucose-regulated expression systems, these transcriptionally regulated systems are relatively slow in the "on-" and "off"-kinetics of insulin production, raising a serious safety concern for clinical application. In this article, we will review recent advances made to address this concern and highlight the importance of insulin gene transfer to cell types that possess an intrinsic ability to kinetically mimic the pancreatic beta cells in terms of glucose-responsive insulin secretion.

AB - Type 1 or insulin-dependent diabetes mellitus is caused by autoimmune attack and selective destruction of the pancreatic beta cells. Despite the development of various insulin replacement therapies, insulin injection still remains the mainstay treatment for type 1 diabetes. However, exogenous insulin administration cannot achieve the same degree of glycemic control as provided by endogenous insulin produced from the pancreatic beta cells. Insulin gene transfer is being developed to improve the quality of glycemic control by restoring endogenous insulin production in type 1 diabetes. Nevertheless, attempts to achieve adequately regulated insulin production are stymied by the lack of appropriate surrogate cells that are able to detect blood glucose variations and release insulin in a glucose-dependent manner. Although limited success has been made to control insulin gene expression in ectopic cells using hormone/glucose-regulated expression systems, these transcriptionally regulated systems are relatively slow in the "on-" and "off"-kinetics of insulin production, raising a serious safety concern for clinical application. In this article, we will review recent advances made to address this concern and highlight the importance of insulin gene transfer to cell types that possess an intrinsic ability to kinetically mimic the pancreatic beta cells in terms of glucose-responsive insulin secretion.

UR - http://www.scopus.com/inward/record.url?scp=1542322876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542322876&partnerID=8YFLogxK

M3 - Article

C2 - 12477252

AN - SCOPUS:1542322876

VL - 2

SP - 403

EP - 414

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 4

ER -